Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 7/7/2020
SIETES contiene 93061 citas

 1 a 20 de 57 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas
Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K. Raising the bar for market authorisation of new drugs. BMJ 2012;345:25-8. [Ref.ID 93567]
2.Tiene citas relacionadas Cita con resumen
Light D, Lexchin J. Pharmaceutical R&D. What do we get for all that money?. BMJ 2012;345:22-5. [Ref.ID 93566]
3. Cita con resumen
Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010;340:641-6. [Ref.ID 88147]
4. Cita con resumen
Anónimo. Sildénafil, tadalafil, vardénafil: allongement de l'intervalle QT. Prescrire 2009;29:265. [Ref.ID 85590]
5. Cita con resumen
Hochberg AM, Pearson RK, O'Hara DJ, Reisinger SJ. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System. Drug Saf 2009;32:137-46. [Ref.ID 85482]
6. Cita con resumen
Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over and 8-year period. Br J Clin Pharmacol 2009;67:88-98. [Ref.ID 84983]
7. Cita con resumen
Tanne JH. FDA adds "black box" warning to fluoroquinolone antibiotics. BMJ 2008;337:135. [Ref.ID 83607]
8. Cita con resumen
Anónimo. Pûblic Citizen sues the FDA over tendon warning for fluoroquinolones. Scrip 2008;3325:13. [Ref.ID 81959]
Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisatioon. Drug Saf 2007;30:705-13. [Ref.ID 80970]
10.Tiene citas relacionadas Cita con resumen
Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007;370:185-91. [Ref.ID 80570]
11. Cita con resumen
12.Tiene citas relacionadas
Gurwitz JH. Serious adverse drug effects - seeing the trees through the forest. N Engl J Med 2006;354:1413-5. [Ref.ID 76605]
13.Tiene citas relacionadas
Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61. [Ref.ID 76603]
14. Cita con resumen
Anónimo. Hypo- and hyperglycemia with gatifloxacin (Tequin). Med Lett Drugs Ther 2006;48:24. [Ref.ID 76570]
15.Tiene citas relacionadas Cita con resumen
Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 2006;367:945-7. [Ref.ID 76381]
Anónimo. Gatifloxacin. Serious effects on blood glucose levels. Canada. WHO Pharmaceuticals Newsletter 2006;1:5-6. [Ref.ID 76319]
17. Cita con resumen
Taylor-Robinson D. The failure of antibiotics to prevent heart attacks. BMJ 2005;331:361-2. [Ref.ID 74617]
Blommel AL, Lutes RA. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother 2005;39:1349-52. [Ref.ID 74463]
19.Tiene citas relacionadas
Seleccionar todas
 1 a 20 de 57 siguiente >>